ahlam1399
09-22-2016, 04:31 PM
UK okays Alexion drug costing up to $2 million but wants price cut
LONDON (Reuters) - A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for use by Britain's health cost watchdog.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=AWNqPuGXq7g:SJMnFt5RLqg:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=AWNqPuGXq7g:SJMnFt5RLqg:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/AWNqPuGXq7g
LONDON (Reuters) - A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for use by Britain's health cost watchdog.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=AWNqPuGXq7g:SJMnFt5RLqg:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=AWNqPuGXq7g:SJMnFt5RLqg:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=AWNqPuGXq7g:SJMnFt5RLqg:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/AWNqPuGXq7g